Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn® 2.25, Zosyn® 4.5), an injectable antibiotic combined with β-lactamase inhibitor

達哉, 宇治; 好和, 橋本

doi:10.1254/fpj.133.351

Cited by 3 publications

(3 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Beta-lactamase inhibitors have generally been combined with penicillins partly because this combination can bring out the antibiotic activity fully and prevent the emergence of antibiotic-resistant strains [5]. TAZ/PIPC (Zosin®) is an intravenous antibiotic agent consisting of 4 g of piperacillin and 0.5 g of tazobactam at an 8:1 ratio and is a modification of Tazosin®, which was used before and consisted of 2 g of piperacillin and 0.5 g of tazobactam [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…TAZ/PIPC (Zosin®) is an intravenous antibiotic agent consisting of 4 g of piperacillin and 0.5 g of tazobactam at an 8:1 ratio and is a modification of Tazosin®, which was used before and consisted of 2 g of piperacillin and 0.5 g of tazobactam [5,6]. Penicillins combined with beta-lactamase inhibitors such as TAZ/PIPC are widely used to treat UTIs and show good efficacy for E. coli , including FQRE and ESBL-producing E. coli , and are recommended for TPBX in the Japanese UTI association guidelines especially in high risk group [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Combination Use of Beta-Lactamase Inhibitor with Penicillin and Fluoroquinolones for Antibiotic Prophylaxis in Transrectal Prostate Biopsy

et al. 2011

View full text Add to dashboard Cite

PurposeTo investigate the efficacy of tazobactam/piperacillin (TAZ/PIPC) plus levofloxacin (LVFX) as a prophylactic administration in transrectal prostate biopsy (TPBX).Materials and MethodsWe investigated 201 consecutive patients who underwent TPBX in one Japanese hospital during the period of 2009-2010. The patients received TAZ/PIPC 4.5 g i.v. once just before and 3 hours after TPBX, plus oral LVFX 300 mg or 500 mg daily for 3 days. We examined the infectious adverse events and laboratory data (serum white blood cell [WBC] count and C-reactive protein [CRP]) before and 1 day after TPBX.ResultsOnly one patient (0.50%) in 201 cases had febrile complications after TPBX. Serum WBC and CRP did not rise significantly on the day after TPBX compared with before TPBX (p>0.05). There was no significant difference in the rise of serum WBC and CRP before and after TPBX in the comparison of LVFX 500 mg with LVFX 300 mg in the TAZ/PIPC plus LVFX regimen.ConclusionsTAZ/PIPC plus LVFX can be considered as a prophylactic regimen for preventing infectious complications in TPBX.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Efficacy of Combination Use of Beta-Lactamase Inhibitor with Penicillin and Fluoroquinolones for Antibiotic Prophylaxis in Transrectal Prostate Biopsy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Also, another study found that the risk of AKI was higher with 4.5 g than with 3.375 g doses of piperacillin-tazobactam in combination with vancomycin (1). In Japan, a low, 2.5-g dose (0.5 g tazobactam and 2.0 g piperacillin) was marketed as a medicine containing tazobactam and piperacillin in 2001 and a high, 4.5-g dose (0.5 g tazobactam and 4.0 g piperacillin) was marketed as such a medicine in 2008 (16).…”

Section: Discussionmentioning

confidence: 99%

Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER

IDE,

SAKO,

TAKIGAWA

et al. 2024

In Vivo

View full text Add to dashboard Cite

Background/Aim: Pharmacovigilance data and clinical studies have indicated a risk of acute kidney injury (AKI) associated with concomitant administration of vancomycin and piperacillin-tazobactam. However, no pharmacovigilance studies have evaluated time-to-onset and outcomes of AKI related to this combination. Therefore, this study used a pharmacovigilance database to investigate the incidence, time-to-onset, and outcomes of AKI in patients treated with intravenous vancomycin plus piperacillintazobactam or other antipseudomonal antibiotics. Patients and Methods: From data in the Japanese Adverse Drug Event Report (JADER) database, we calculated the reporting odds ratios (RORs) and 95% confidence intervals (CIs), time-toonset, and outcomes of AKI following intravenous administration of vancomycin plus piperacillin-tazobactam or other antipseudomonal antibiotics and with other vancomycin regimens, including monotherapy. Results: The JADER database contained 4,471 reports of intravenous vancomycin treatment, including 517 reports of AKI. The adjusted RORs (95%CIs) of AKI in cases with co-administration of intravenous vancomycin and piperacillin-tazobactam was 2.58 (2.06-3.24). The median time-to-onset for AKI in vancomycin plus piperacillin-tazobactam was 6.0 (interquartile range=3.0-10.3). Weibull shape parameter analysis showed that the pattern of onset of AKI in vancomycin plus piperacillintazobactam represented a wear out failure, predicting an increasing hazard with time. For the outcome of AKI, there was no significant difference between all vancomycin regimen and the piperacillin-tazobactam combination groups. Conclusion: Concomitant use of intravenous vancomycin and piperacillintazobactam may increase the incidence of AKI but may not affect the outcome. This combination does not necessarily have to be avoided, but long-term use is not advisable.

show abstract

Adjuvant Molecules/Compounds in Combating Bacterial Resistance

Shadab¹,

Shahid²

2022

Beta-Lactam Resistance in Gram-Negative Bacteria

View full text Add to dashboard Cite

Pharmacological properties and clinical efficacies of tazobactam/piperacillin (Zosyn® 2.25, Zosyn® 4.5), an injectable antibiotic combined with β-lactamase inhibitor

Cited by 3 publications

References 12 publications

Efficacy of Combination Use of Beta-Lactamase Inhibitor with Penicillin and Fluoroquinolones for Antibiotic Prophylaxis in Transrectal Prostate Biopsy

Efficacy of Combination Use of Beta-Lactamase Inhibitor with Penicillin and Fluoroquinolones for Antibiotic Prophylaxis in Transrectal Prostate Biopsy

Risk and Time-to-Onset of Acute Kidney Injury With Vancomycin Plus Piperacillin-tazobactam Combination: Analysis Using JADER

Adjuvant Molecules/Compounds in Combating Bacterial Resistance

Contact Info

Product

Resources

About